ALEMBIC PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 965.6 INR | -0.30% |
|
-2.49% | +27.15% |
| Sales 2024 * | 63.38B 759M | Sales 2025 * | 70.38B 842M | Capitalization | 190B 2.28B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.95B 71.23M | Net income 2025 * | 7.03B 84.13M | EV / Sales 2024 * | 3.04 x |
| Net Debt 2024 * | 2.62B 31.32M | Net cash position 2025 * | 457M 5.48M | EV / Sales 2025 * | 2.7 x |
| P/E ratio 2024 * |
32.1
x | P/E ratio 2025 * |
27
x | Employees | 14,593 |
| Yield 2024 * |
0.92% | Yield 2025 * |
1.04% | Free-Float | 29.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alembic Pharmaceuticals Limited
More recommendations
More press releases
| 1 day | -0.06% | ||
| 1 week | -2.25% | ||
| Current month | -1.71% | ||
| 1 month | +0.49% | ||
| 3 months | +2.81% | ||
| 6 months | +19.98% | ||
| Current year | +27.47% |
1 week
950.40
1 004.85
1 month
924.251 049.00
Current year
773.401 094.00
1 year
517.051 094.00
3 years
462.301 094.00
5 years
434.801 145.00
10 years
227.001 145.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 83-04-30 | |
| Director of Finance/CFO | 64 | 03-01-17 | |
Manisha Saraf
CMP | Compliance Officer | - | 23-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 83-04-30 | |
| Director of Finance/CFO | 64 | 03-01-17 | |
| Director/Board Member | 56 | 15-02-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -0.19% | - | |
| 0.00% | 34 M€ | +2.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 965.6 | -0.30% | 53 601 |
| 24-04-15 | 968.6 | -1.43% | 57,393 |
| 24-04-12 | 982.6 | -1.12% | 92,575 |
| 24-04-10 | 993.8 | +0.35% | 77,497 |
| 24-04-09 | 990.3 | -1.48% | 91,520 |
Delayed Quote NSE India S.E., April 15, 2024 at 11:56 pm EDT
More quotes
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
968.6
INR
Average target price
933.5
INR
Spread / Average Target
-3.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.47% | 2.31B | |
| +28.79% | 677B | |
| +25.94% | 560B | |
| -5.84% | 355B | |
| +15.75% | 319B | |
| +4.32% | 287B | |
| +4.00% | 214B | |
| +1.92% | 207B | |
| -7.93% | 199B | |
| -10.00% | 146B |
- Stock Market
- Equities
- APLLTD Stock
